DCF Advisers LLC Has $8.33 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

DCF Advisers LLC reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 99,757 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. Intra-Cellular Therapies comprises 4.0% of DCF Advisers LLC’s investment portfolio, making the stock its 4th biggest position. DCF Advisers LLC’s holdings in Intra-Cellular Therapies were worth $8,332,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC lifted its stake in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $97,000. Finally, Quarry LP lifted its stake in shares of Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 1,300 shares in the last quarter. 92.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Piper Sandler restated a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $131.60 on Friday. The company’s fifty day moving average price is $127.87 and its 200-day moving average price is $97.01. The firm has a market capitalization of $13.99 billion, a price-to-earnings ratio of -151.26 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.60.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.